Introduction
============

Congenital fibrosis of the extraocular muscles type 1 (CFEOM1, OMIM [135700](http://www.ncbi.nlm.nih.gov/omim/135700)) is the most common form of CFEOM reported worldwide \[[@r1]\]. It is a distinct non-syndromic congenital cranial dysinnervation disorder and is characterized by bilateral ptotic hypotropia, an inability to supraduct above the horizontal midline, horizontal strabismus (typically exotropia), and a variable degree of ophthalmoplegia with abnormal synkinesis \[[@r2]-[@r4]\]. The phenotype was first mapped as an autosomal dominant fully penetrant trait to the centromere on chromosome 12 \[[@r5]\]. Screening of transcripts in this region in several affected families lead to the discovery of heterozygous missense mutations in kinesin family member 21A (*KIF21A*) as the cause \[[@r2]\]. Since then further studies provide strong evidence that the classic CFEOM1 phenotype results from mutations in *KIF21A* and that sporadic cases are due to de novo mutations in the same gene \[[@r1]-[@r3],[@r6]-[@r14]\]. A heterozygous *KIF21A* missense mutation has been found to underlie CFEOM1 patients across populations worldwide with most patients having mutations in exon 21 that affect arginine at position 954 of the protein (p.R954W, p.R954Q, or p.R954L) \[[@r1]-[@r3]\]. It has been suggested that methylation of CpG dinucleotides in exon 21 of *KIF21A* increases susceptibility to mutational events \[[@r13]\]. Other than exon 21, only 2 other exons in the 38-exon gene have been reported to harbor mutations: exon 8 (p.M356T) and exon 20 (p.E944Q, p.M947V, p.M947T, p.M947R) \[[@r3]\]. The lack of mutations in other exons of *KIF21A* and the lack of other types of mutations (other than missense) may be because such mutations are lethal or because they underlie a phenotype thus far not associated with the gene. The normal function of the KIF21A protein includes the transport of membranous organelles, protein complexes, and mRNAs to specific destinations within the cell in a microtubule- and ATP-dependent manner. These functions are essential for normal morphogenesis and functioning of the cell \[[@r15]\]; however, missense *KIF21A* mutations only appear to significantly affect the orbit, causing widespread orbital dysinnervation \[[@r16]\].

Other clinical forms of CFEOM with a known genetic basis are CFEOM2 (OMIM [602078](http://www.ncbi.nlm.nih.gov/omim/602078)) and CFEOM3 (OMIM [600638](http://www.ncbi.nlm.nih.gov/omim/600638)). CFEOM2, the rarest CFEOM phenotype, is a recessive disorder that was first mapped to 11q13 in consanguineous families \[[@r17]\] and later found to be secondary to homozygous mutations in the hindbrain transcription factor paired-like homeobox 2A (*PHOX2A*) \[[@r18]\]. *PHOX2A* knockout animal models reveal that the gene is responsible for development of the oculomotor and trochlear cranial nerve nuclei \[[@r19],[@r20]\]. The CFEOM2 phenotype is characterized by bilateral large-angle exotropia, ptosis, miosis, and ophthalmoplegia with abnormal synkinesis \[[@r4],[@r21]\]. CFEOM3 is CFEOM that does not meet the classic criteria for CFEOM1 or CFEOM2. CFEOM3 can be unilateral or bilateral, is often autosomal dominant, and can have variable penetrance \[[@r4],[@r22],[@r23]\]. A family with autosomal dominant CFEOM is considered to be a CFEOM3 pedigree even if one or more members has (have) classic CFEOM1 if at least one affected family member does not meet the criteria for CFEOM1 \[[@r4],[@r23]\]. Most CFEOM3 families have mapped to 16qter \[[@r23]-[@r25]\] and are due to heterozygous mutation in tubulin beta-3 (*TUBB3*), a gene involved in microtubule dynamics, kinesin interactions, and axon guidance \[[@r22]\]. Unlike patients with CFEOM1 or CFEOM2, patients with *TUBB3*-related CFEOM3 can have extraorbital neurologic findings as well \[[@r2]\]. In some instances, CFEOM3 can be caused by heterozygous missense *KIF21A* mutations \[[@r23]\].

CFEOM1 is considered to be an autosomal dominant fully penetrant condition. Although *KIF21A* is the only gene associated with CFEOM1 to date, up to 40% of sporadic CFEOM1 cases do not have identifiable mutations in *KIF21A* \[[@r3]\]. Among the possibly genetic causes are mutations in a *KIF21A* promotor, mutations in *PHOX2A* and/or *TUBB3*, or dominant or recessive mutations at a different locus. If a recessive cause for CFEOM1 exists, one would expect it to occur more commonly in CFEOM1 patients from large consanguineous families \[[@r26]\]. In the current study, we perform candidate gene testing in CFEOM1 patients from consanguineous families to explore the possibility of a recessive cause for the CFEOM1 phenotype.

Methods
=======

Institutional board approval was granted for this study. Only probands with CFEOM1 who were from consanguineous families were invited to participate in the study. Enrolled patients, who had no known relationship to each other, had complete orthoptic and ophthalmic examination as well as 5 ml venous blood sampling for candidate gene testing and were referred to one of the authors (A.O.K.) from 2005 to 2010. Cyclopentolate 1% was used for dilation and cycloplegic refraction. When affected relatives were available and willing, they were examined as well. The candidate genes *KIF21A*, *PHOX2A*, and *TUBB3* were directly sequenced. Briefly, polymerase chair reaction products from all exons of *KIF21A* ([NM_017641](http://www.ncbi.nlm.nih.gov/nuccore/291167758)), *PHOX2A* ([NM_005169](http://www.ncbi.nlm.nih.gov/nuccore/188536104)), and *TUBB3* ([NM_006086.2](http://www.ncbi.nlm.nih.gov/nuccore/50592995)) were sequenced using the ABI Prism Big Dye Terminator v3.1 Cycle Sequencing Kit as described by the manufacturer. Results were exported in one of several formats for visualization and sequence was analyzed using SeqMan 6.1 (Lasergene 6 software package) \[[@r22],[@r27]\]. Primers used for *KIF21A* are shown in [Table 1](#t1){ref-type="table"}, for *PHOX2A* are shown in [Table 2](#t2){ref-type="table"}, and for *TUBB3* are shown in [Table 3](#t3){ref-type="table"} and are as previously published \[[@r22]\].

###### Primers for *KIF21A.*

  **Exon**             **5′ to 3′ primer sequence**   **PCR conditions**
  -------------------- ------------------------------ --------------------
  Kfi21a_x1Fn          ctgttggcttctccacagg            52 °C/35 cycles
  Kfi21a_x1Rn          gggactcactgcctcagttt            
  Kfi21a_x2Fn          tcatgattttgggggattgt           53 °C/35 cycles
  Kfi21a_x2Rn          caaaaatgaaagcgcaactg            
  Kif21a_x3F           tcagttgcgctttcatttttg          53 °C/35 cycles
  Kif21a_x3R           ctccaacctgggtgacagaa            
  Kif21a \_x4F         tagcctcattcattttaatgtgtt       59 °C/35 cycles
  Kif21a \_x4R         gatcttaattccatgtcatgcttc        
  Kif21a \_x5F         tgcctgtaactgaactaataatgtga     59 °C/35 cycles
  Kif21a \_x5R         atggctgaccagcttcaact            
  Kif21a \_x6F         tttggctttatgcctgtttc           59 °C/35 cycles
  Kif21a \_x6R         tgaggagattggagattcagtg          
  Kif21a_x7F           cttatttctgtttcaaagaattagta     59 °C/35 cycles
  Kif21a_x7R           cctacacctcaagggatgct            
  Kif21a \_x8F         caggggcttttaaatttgct           59 °C/35 cycles
  Kif21a \_x8R         ctccaaaaggaaggaggaca            
  Kif21a_x9Fn          tggtcttgaactcctgacctc          59 °C/ 35 cycles
  Kif21a_x9rn          tgccctccagaagttaatcc            
  Kif21a_x10F          tgtggtctgctcatgtaataaagg       53 °C/35 cycles
  Kif21a_x10R          ggaatatgacatcaagggaaagg         
  Kif21a_x11Fn         ccacagagaaaaatgctcccta         59 °C/35 cycles
  Kif21a_x11Rn         tgaatggaatgcaaaagcag            
  Kif21a \_x12F        gcatccaagcatgcctaatc           59 °C/35 cycles
  Kif21a \_x13R        tttaggagcagcccagctta            
  Kif21a_x13Fn         tgattggcaatttccattttt          59 °C/35 cycles
  Kif21a_x13Rn         gactccccaacacaatgctt            
  Kif21a \_x14F        gttggggagtcaggggtaga           56 °C/35 cycles
  Kif21a \_x14R        taaagccttggaaggcaaatg           
  Kif21a \_x15F        cattcaccttttggttgttgg          59 °C/35 cycles
  Kif21a \_x15R        aggcacaaactttgacttgc            
  Kif21a \_x16F        gacaccctagtcttctgagatgtg       59 °C/35 cycles
  Kif21a \_x16R        ttgccaaaggaaattacatca           
  Kif21a \_x17F        taaacgtgcagcaaaactgc           59 °C/35 cycles
  Kif21a \_x17R        tgcttatctattgtccttaacctgc       
  Kif21a x18F          tggccgttaatactgaatgttg         56 °C/35cycles
  Kif21a x18R          aaagcaggttggattttaagaaa         
  Kif21a_x19F          ccatttggaagaaaccttctg          56 °C/35 cycles
  Kif21a_x19R          tgcactgccaaataatgagc            
  Kif21a \_x20--21F    ggcaacaaatggaaacaggt           59 °C/35 cycles
  Kif21a \_x20--21R    tggcatacatgtaaaacctaagc         
  Kif21a \_x22F        ccctatgtttcttggggtaatgat       59 °C/35 cycles
  Kif21a \_x22R        tccttattacaaagcaaagggtta        
  Kif21a \_x23--24F    ttactggaggagctgggatg           59 °C/35 cycles
  Kif21a \_x23--24R    tagtgtgtttgtgggcatgg            
  Kif21a \_x25\_ 26F   actaaaaccatcgtgcccat           59 °C/35 cycles
  Kif21a \_x25\_ 26R   gctttagtaaaaccatgccctc          
  Kif21a 26F           tggcctagtgaatagcacttagaa       59 °C/35 cycles
  Kif21a 26R           cagttaccacttaaagggaaatatga      
  Kif21a \_x27F        cacacctaggaaaagacacgct         56 °C/35 cycles
  Kif21a \_x27R        ggggagacaacacctagcaa            
  Kif21a_x28F          caagtaataatctttctgaggttcca     56 °C/35 cycles
  Kif21a_x28R          accacagcaccagcctaaat            
  Kif21a \_x29F        ttgttcagaatgcattttatcttaca     59 °C/35 cycles
  Kif21a \_x29R        gcatggttcctttcccatt             
  Kif21a \_x30F        agcagggcactatgaaggaa           56 °C/35 cycles
  Kif21a \_x30R        tttatctaaaaggtatgaccacaaaa      
  Kif21a_x31Fn         tgtctcattccctttcacca           56 °C/35 cycles
  Kif21a_x31Rn         caacagacttgatctgaaggaga         
  Kif21a \_x32F        gcttaaaagagagcagtfctgga        59 °C/35 cycles
  Kif21a \_x32R        ggttgaaccagattatccga            
  Kif21a \_x33F        tgaagttaggatccttgtggtatg       59 °C/35 cycles
  Kif21a \_x33R        tgggaagtggacaggtatacaa          
  Kif21a \_x34F        tgtgttaggtgctgtgctagg          56 °C/35 cycles
  Kif21a \_x34R        aaggacacaagagacatttagagg        
  Kif21a \_x35F        gcccaagatcccatctctaa           56 °C/35 cycles
  Kif21a \_x35R        ccactaactatgaatgaaggaaaaga      
  Kif21a_x36Fn         ctccagcctgggaaacatag           59 °C/35 cycles
  Kif21a_x36Rn         ggcctgattaatattatctgtaaatga     
  Kif21a \_x37F        ctttctccagccaattccaa           59 °C/35cycles
  Kif21a \_x37R        aacctggggtgcctaaattc            
  Kif21a \_x38F        tgtaaagggcacatggtaacaa         59 °C/35 cycles
  Kif21a \_x38R        gcagttgaattcagatatattttcca      

###### Primers for *PHOX2A*.

  **Exon**       **5′ to 3′ primer sequence**   **PCR conditions**
  -------------- ------------------------------ --------------------
  Phox2ax1.1Fn   tccacacctctgagccctaagacgg      63 °C/DMSO10%
  Phox2ax1.1Rn   gccgcagggggctgtattggaagc        
  Phox2ax1.2fn   ccccgggccgatggactact           63 °C/DMSO10%
  Phox2ax1.2Rn   agcgggcccagggattc               
  Phox2ax2fn     tcactcccccatcctttttgc          57 °C/35 cycles
  Phox2ax2Rn     gctcccacacctccttcca             
  Phox2ax3.1fn   gatctcactcgagccttgc            57 °C/35 cycles
  Phox2ax3.1Rn   ctgcacgtggactccttgga            
  Phox2ax3.2fn   cgggccaagttccgcaaacaggag       57 °C/35 cycles
  Phox2ax3.2Rn   ggacgtctctgggggcaggctcgga       

###### List of primers for *TUBB3*.

  **Exon**     **5' to 3' sequence**   **Product size**   **Temperature/cycles**
  ------------ ----------------------- ------------------ ------------------------
  TUBB3X1F     ggccgcggctataagag       272                56 °C /35
  TUBB3X1R     catccctttgttgcaggttc                        
  TUBB3X2F     tgggtcaaaagccctaatttt   317                56 °C /35
  TUBB3X2R     ctgagagctggtgagtccag                        
  TUBB3X3F     gctcttaggatgtgagcagga   323                56 °C /35
  TUBB3X3R     ggagctgaccattccttgtt                        
  TUBB3X4-1F   atgagaaggggtgctcagtg    489                56 °C /35
  TUBB3X4-1R   ctcgttgtcgatgcagtagg                        
  TUBB3X4-2F   cgcatcatgaacaccttcag    498                56 °C/35
  TUBB3X4-2R   gtccacctccttcatggaca                        
  TUBB3X4-3F   agctcacccagcagatgttc    594                56 °C /35
  TUBB3X4-3R   gaggggaaagcagggtgt                          

Sequences in Table are based on \[[@r22]\].

Results
=======

Pedigrees for the 5 patients are shown in [Figure 1](#f1){ref-type="fig"}. All 5 probands had classic CFEOM1 without pupillary abnormality as defined above. One proband had an affected sibling with CFEOM1 (family 3 in [Figure 1](#f1){ref-type="fig"}) and 2 probands each had an affected sibling with CFEOM3 (unilateral CFEOM ; families 4 and 5 in [Figure 1](#f1){ref-type="fig"}). Clinical features of the probands are summarized in [Table 4](#t4){ref-type="table"} and the typical proband phenotype is shown in [Figure 2](#f2){ref-type="fig"} (patient 1 from [Table 4](#t4){ref-type="table"}). No patient had significant extra-orbital disease.

![Pedigrees for the five CFEOM probands (arrow indicates proband). All individuals indicated as affected were confirmed to be affected to have CFEOM by examination. Question mark indicates that the individual was described as having strabismus but was not available for confirmatory ophthalmic examination.](mv-v17-218-f1){#f1}

###### Summary of clinical features.

  **ID**   **Age**   **Sex**   **Total siblings**   **Family history**                      **BCVA**   **Primary**   **AB/AD**   **UP/DN**   **CycloRef**      **Comments**
  -------- --------- --------- -------------------- --------------------------------------- ---------- ------------- ----------- ----------- ----------------- ---------------------------------------------------
  1        7         M         5                    none                                    20/20      xt/hypo       −4/-2       −6/-1       +0.50             attempt up=ad
                                                                                            20/30      xt/hypo       −4/-2       −6/-1       +0.50             attempt up=ad
  2        7         M         3                    maternal uncle with bilateral ptosis    20/40      xt/hypo       −4/-2       −6/-1       +2.00--2.75x015   attempt up=ad
                                                                                            20/400     xt/hypo       −4/-2       −6/-1       −5.00--2.00x150   attempt up=ad
  3        9         F         6                    Younger sister with CFEOM1              20/70      xt/hypo       −1/-1       −5/0        +2.50--2.00x180   attempt ad=dn; attempt up=ad
                                                                                            20/60      xt/hypo       −1/-1       −5/0        +3.50--3.25x180   attempt ad=dn; attempt up=ad
  4        13        F         6                    Older brother with CFEOM3 in left eye   20/30      et/hypo       −2/0        −5/0        +2.00             attempt ab=dn; attempt up=ad; torsional nystagmus
                                                                                            20/25      et/hypo       −3/0        −5/0        +2.00             attempt up=ad; torsional nystagmus
  5        17        F         11                   Older sister with CFEOM3 in left eye    20/40      xt/hypo       −2/-3       −5/-3       +2.00             attempt up=dn&ad
                                                                                            20/60      xt/hypo       −2/-1       −5/-3       +8.00             attempt up=ab

For each patient where relevant, first row represents right eye data and second row represents left eye data; AGE:age in years; F:female; M:male; BCVA:best-corrected visual acuity; CSM:central steady maintained; et:esotropia; xt:exotropia; hypo: hypotropia;ab/ad:limitation of abduction/adduction on a scale of 0 to −4 (−5=eye cannot reach primary); CycloRef:cycloplegic refraction; up/down:limitation of supraduction/infraduction on a scale of 0 to −4 (−5=eye cannot reach primary); attempted x=y: when x attempted, y inappropriately occurs (dysinnervation).

![Typical CFEOM1 phenotype. Patient 1 is shown in forced primary position with his eyelids held upward. He has bilateral blepharoptosis, exotropia, hypotropia, and almost complete ophthalmoloplegia. When released, he assumes a chin up position with a left face turn (because of preference for the right eye).](mv-v17-218-f2){#f2}

No proband had mutations or polymorphic variations in *KIF21A*, *PHOX2A*, or *TUBB3*.

Discussion
==========

Five CFEOM1 probands from consanguineous families were assessed in this study, none of whom had significant extra-orbital disease. Two were sporadic cases, one had a sibling with CFEOM1, and 2 each had a sibling with CFEOM3. No proband from this unique CFEOM1 cohort harbored mutations in *KIF21A*, *TUBB3*, or *PHOX2A*. Rather than being an autosomal dominant phenotype, CFEOM1 in our cohort was almost certainly related to homozygous mutations in a locus (or in loci) that to date has (or have) not been associated with the condition.

The 3 previously-reported CFEOM1 families from Saudi Arabia were not consanguineous and all harbored heterozygous missense *KIF21A* mutations \[[@r6],[@r9]\]. Two families had autosomal dominant inheritance and both harbored the most common *KIF21A* mutation reported worldwide, p.R954W \[[@r9]\]. The third family, of Jordanian ancestry, exhibited apparent autosomal recessive inheritance with atypical abnormal pupils but in fact harbored heterozygous p.R954L KIF21A mutation with parental germline mosaicism \[[@r6]\]. In the current series, none of the 5 CFEOM1 patients harbored mutations in known CFEOM genes. Two cases were sporadic and 3 had affected siblings. For one, the sibling also had CFEOM1 (family 3 from [Figure 1](#f1){ref-type="fig"}). For the other 2, the each had an affected sibling with CFEOM3 (families 4 and 5 from [Figure 1](#f1){ref-type="fig"}). These latter 2 families would be considered by some authors as CFEOM3 pedigrees \[[@r4],[@r23]\].

Studies of consanguineous families are more likely to uncover recessive cause for a given phenotype if a recessive cause exists because of parental shared recent ancestry. Although every individual is a heterozygous carrier for mutated alleles that would potentially cause recessive disease in the homozygous (or compound heterozygous) state, it is unlikely that the individual\'s spouse will carry the same disorder unless they are related \[[@r28]\]. Thus studies of exclusively consanguineous families with a specific phenotype offer a unique opportunity to uncover a recessive cause for the phenotype if a recessive cause exists. Our study confirms the existence of recessive CFEOM1. There may be one or more such loci, each of which may be a separate gene or locus that regulates pathways in known genes associated with CFEOM. Whether the 2 families that included a sibling with CFEOM3 (families 4 and 5 from [Figure 1](#f1){ref-type="fig"}) are considered CFEOM3 families or families with CFEOM1 probands, the observed phenotype is likely related to a recessive cause that has not yet been described.

In summary, although most CFEOM1 is due to heterozygous missense *KIF21A* mutations, there exists at least one additional autosomal recessive cause for the phenotype. This information is useful in the genetic counseling of sporadic *KIF21A*-negative CFEOM1 patients. It is hoped that further ascertainment and study of CFEOM1 patients from consanguineous families will uncover the novel locus(loci).
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